A case of crescentic glomerulonephritis and acute tubulointerstitial nephritis requiring temporary hemodialysis during nivolumab treatment for renal cell carcinoma

Uwatoko Ryuta, Kani Nao, Makino Syuzo, Naka Tomoya, Okamoto Kazuhiro, Miyakawa Hiromitsu, Hashimoto Nobuhiro, Iio Rei, Ueda Yoshiyasu, Hayashi Terumasa

doi:10.4009/jsdt.55.595

Bibliographic Information

Other Title

腎細胞癌に対してニボルマブ投与中に半月体形成性糸球体腎炎ならびに急性尿細管間質性腎炎をきたし一時的に血液透析を要した1 例
ジンサイボウガンニタイシテニボルマブトウヨチュウニハンツキタイケイセイセイシキュウタイジンエンナラビニキュウセイニョウサイカンカンシツセイジンエンオキタシイチジテキニケツエキトウセキオヨウシタ 1レイ

Search this article

Abstract

<p>A 76-year-old male underwent left nephrectomy for left renal cell carcinoma in July X-3. In July X-2, metastasis to the left crus of the diaphragm was confirmed. He was treated with pazopanib and axitinib, but the disease progressed. He was treated with heavy particle irradiation. However, in February X metastasis was detected in the upper lobe of the right lung, and he was started on nivolumab. Before the start of the nivolumab treatment, he had a serum creatinine level (S-Cr) of 1.52 mg/dL, and urinary tests produced the following results：urinary protein (–) and urinary occult blood (–). He received 240 mg nivolumab every 2 weeks for a total of 4 doses. After that, his S-Cr increased to 3.6 mg/dL. He was referred to our department and admitted in June X. On the 8th day, a renal biopsy was performed. Crescentic glomerulonephritis and acute tubulointerstitial nephritis were diagnosed. Steroid therapy was started on the 12th day. Although he needed hemodialysis for 2 weeks, he achieved a partial renal recovery. As crescentic glomerulonephritis caused by immune checkpoint inhibitors is rare, further case accumulation is needed.</p>

Journal

Nihon Toseki Igakkai Zasshi

Nihon Toseki Igakkai Zasshi 55 (10), 595-601, 2022

The Japanese Society for Dialysis Therapy

Keywords

Details 詳細情報について

Export